Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Direct Access Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

J&J subsidiary's Confide home HIV testing system should be approved by FDA immediately in order to encourage more people to seek testing, a Washington, D.C.-based conservative think-tank, Coalitions for America, urged at a Dec. 13 press briefing. Calling FDA's inaction on the company's seven-year-old premarket approval application for the device "unconscionable," Coalitions Chairman Paul Wayrich said "the government's own data indicate that the number of Americans who would get testing if the home option were available more than triples." Joined by the Institute for Justice, the Coalitions for America said continued delays in getting the home-use HIV kits to market may result in "a legislative remedy," which "is now very possible given the new political realities in Washington"

Latest Headlines
See All
UsernamePublicRestriction

Register

MT003207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel